NCT06657703View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.

PHASE1RecruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

January 8, 2026

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

HC022

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (3)

100730

NOT_YET_RECRUITING

Peking Union Medical College Hospital, Beijing

Unknown

RECRUITING

Peking Union Medical College Hospital, Beijing

RECRUITING

The Clinical Pharmacology Research Center of PUMCH, Beijing

Sponsors

Lead Sponsor

HC Biopharma Inc.
All Listed Sponsors
lead

HC Biopharma Inc.

INDUSTRY

NCT06657703 - Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects. | Biotech Hunter | Biotech Hunter